Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.

Giorgio Lambertenghi‐Deliliers(Ospedale Maggiore), Polli Ee(University of Milan), R. Mozzana(University of Milan), Della Volpe A(University of Milan), E Pozzoli(University of Milan), M. Cortellaro(University of Milan), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Enrico Pogliani(Azienda Ospedaliera San Gerardo), Maiolo At(University of Milan), C. Annaloro(University of Milan)

PubMed

February 1, 1989

Cited by 12

Related Papers

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

|Blood|2009|433

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

|Journal of Clinical Oncology|2016|394

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients

|Blood|2014|373

Angiogenesis in myelodysplastic syndromes

|British Journal of Cancer|1999|272

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

|Blood|2008|253